Daniel Lin

9PUBLICATIONS
5CO-AUTHORS
Tumour immunologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Social epidemiologyFood properties (incl. characteristics and health benefits)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 15, 2026
Neoadjuvant Immunotherapy for Hepatocellular Carcinoma Is Associated with Improved Survival After Hepatectomy: A Matched Analysis of the 2017 to 2022 National Cancer Database.

|Mar 14, 2026
Predicting and Managing Hepatocellular Carcinoma Recurrence After Liver Transplant: A Single-Center Experience 2012-2024.

Jesse Civan, Madison Force, Ali Raza Shaikh

|Jul 09, 2025
Q-TWiST analysis of first-line nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma from CheckMate 649: 4-year follow-up results.

Daniel Lin, Wenying Quan, Marne Garretson

|Nov 18, 2024
Liposomal eribulin (E7389-LF) plus nivolumab: a potential treatment option for patients with advanced gastric cancer?

Ali Raza Shaikh, Daniel Lin

|Apr 19, 2024
Race/ethnicity and socioeconomic position in emergency department utilization in patients with hepatocellular carcinoma.

Daniel Lin, Ruoding Tan, Christie Teigland

|Mar 21, 2023
Quality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.

Daniel Lin, Hiep Nguyen, Ruchit Shah

Pageof 2

Frequent Collaborators

2 joint publications

Adam Bodzin

1 joint publications

Karl M Kilgore

1 joint publications

Hien Dang

1 joint publications

Charles J Yeo